MLTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

MLTX ▼ -12.74% at T+5d

LONG call ✗ call lost -12.74% · α vs SPY -12.65% · entry $18.84 → $16.44

Next anchor: T+20d in 19d

Currently $17.05 · -9.50% from $18.84 entry

Entry anchored
May 10, 2026
via day open

T+1d

-3.45%

call -3.45% · α -3.31%

$18.19

settled 9d ago

T+5d

-12.74%

call -12.74% · α -12.65%

$16.44

settled 5d ago

T+20d

—

call — · α —

—

in 19d

T+60d

—

call — · α —

—

in 3mo

Price Chart

Loading chart...

Executive Summary

MoonLake announced a successful final pre-BLA meeting with the FDA, aligning on submission plans and label strategy for sonelokimab in hidradenitis suppurativa (HS), including inclusion of adolescent data. The BLA submission is planned for end of September 2026, with potential Priority Review decision by end of November 2026. Q1 2026 cash position of $357.9M provides runway to end of 2027, with up to $400M in non-dilutive debt available.

Actionable Insight

The successful pre-BLA meeting significantly de-risks the regulatory path for sonelokimab in HS, a key catalyst. Monitor for BLA acceptance and Priority Review decision by end of November 2026, and upcoming data readouts (52-week VELA data in Q2 2026, IZAR-1 PsA data mid-2026). Cash runway through end of 2027 and $400M debt facility provide ample funding. The stock may re-rate on reduced regulatory risk.

Key Facts

Positive final pre-BLA meeting with FDA; no remaining gaps identified for HS program
BLA submission for sonelokimab in HS planned for end of September 2026
FDA acceptance and Priority Review decision expected by end of November 2026
Proposed label expected to include MIRA trial's ~43% HiSCR75 response and ~29 ppt delta-to-placebo
First commercial launch in US expected in second half of 2027
Q1 2026 cash, cash equivalents and short-term marketable debt securities: $357.9M
Cash runway expected to end of 2027; up to $400M non-dilutive debt facility with Hercules Capital available
R&D expenses $54.5M for Q1 2026, similar to $56.0M in Q4 2025
Net loss $69.7M for Q1 2026 vs $63.0M in Q4 2025

Financial Impact

No revenue or EPS reported (pre-revenue biotech). Cash burn rate ~$70M/quarter. BLA submission de-risks path to approval and potential $15B HS market by 2035.

cashburn ratedevelopment timeline

Risk Factors

BLA submission or review could face delays or unexpected FDA requests
Priority Review may not be granted, extending review timeline
Commercial launch in 2H 2027 is subject to FDA approval and could be delayed
Competition from approved IL-17 inhibitors (e.g., secukinumab, bimekizumab) in HS
Clinical data from ongoing trials (VELA-TEEN, IZAR) could disappoint

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

78% bullish (23 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3291475

3 reports for MLTX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for MLTX — sortable, filterable
	Type				Now
May 10, 2026 10d ago	Press Release BULLISH ★ 7/10	$18.84 $16.44	▼ −12.74%	▼ −12.65%	$17.05 (−9.50%)
Apr 1, 2026 7w ago	144 BEARISH ★ 6/10	$16.52 $19.41	▼ −17.49%	▼ −13.73%	$17.05 (−3.21%)
Mar 28, 2026 7w ago	Press Release BULLISH ★ 8/10	$16.93 $17.08	▲ +0.89%	▼ −3.41%	$17.05 (+0.71%)

US Market Status

Market Closed — Opens Thu (< 1m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access